These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 8402671)

  • 1. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
    Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
    Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL; Brown TD; Kuhn JG; Shen HS; O'Rourke TJ; Beougher K; Brentzel HJ; Von Hoff DD; Weiss GR
    Cancer Res; 1989 Aug; 49(16):4648-53. PubMed ID: 2743343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.
    Vogelzang NJ; Mani S; Schilsky RL; Ansari RH; Taber D; Rhinehart SN; Garcia JC; Meyer SC; Mick R; Brockstein BE; Stadler WM; Ratain MJ; Vokes EE
    Clin Cancer Res; 1998 Apr; 4(4):929-34. PubMed ID: 9563886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors.
    Pitot HC; McElroy EA; Reid JM; Windebank AJ; Sloan JA; Erlichman C; Bagniewski PG; Walker DL; Rubin J; Goldberg RM; Adjei AA; Ames MM
    Clin Cancer Res; 1999 Mar; 5(3):525-31. PubMed ID: 10100703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y; Amano T; Morita M; Shinkai T; Eguchi K; Tamura T; Ohe Y; Kojima A; Saijo N
    Cancer Res; 1991 Mar; 51(5):1472-7. PubMed ID: 1997185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.
    Madden T; Tran HT; Beck D; Huie R; Newman RA; Pusztai L; Wright JJ; Abbruzzese JL
    Clin Cancer Res; 2000 Apr; 6(4):1293-301. PubMed ID: 10778954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.
    Bailey H; Tutsch KD; Arzoomanian RZ; Tombes MB; Alberti D; Bruggink J; Wilding G
    Cancer Res; 1991 Feb; 51(4):1105-8. PubMed ID: 1705165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and clinical pharmacology trial of 502U83 using a monthly single dose schedule.
    Von Hoff DD; Kuhn JG; Havlin KA; Langevin AM; Brown TD; Weiss GR; Turner JN; Purvis J; Lucas VS; Bair KW
    Cancer Res; 1990 Dec; 50(23):7496-500. PubMed ID: 2253197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.
    Schilder RJ; LaCreta FP; Perez RP; Johnson SW; Brennan JM; Rogatko A; Nash S; McAleer C; Hamilton TC; Roby D
    Cancer Res; 1994 Feb; 54(3):709-17. PubMed ID: 8306332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of hepsulfam (NSC 329680).
    Hendricks CB; Grochow LB; Rowinsky EK; Forastiere AA; McGuire WP; Ettinger DS; Sartorius S; Lubejko B; Donehower RC
    Cancer Res; 1991 Nov; 51(21):5781-5. PubMed ID: 1933848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.
    Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ
    Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole.
    Hantel A; Donehower RC; Rowinsky EK; Vance E; Clarke BV; McGuire WP; Ettinger DS; Noe DA; Grochow LB
    Cancer Res; 1990 Jun; 50(11):3284-8. PubMed ID: 2334921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.